Quest Diagnostics director adds shares via DRIP

Quest Diagnostics director Robert B. Carter reported a small acquisition of company stock through a dividend reinvestment plan.

Rhea-AI Filing Summary

Quest Diagnostics director Robert B. Carter reported a small acquisition of company stock through a dividend reinvestment plan. On January 28, 2026, he acquired 6 shares of common stock at $183.51 per share. Following this routine reinvestment, he directly owns 2,704 shares of Quest Diagnostics common stock. The transaction was eligible for later reporting on Form 5, but he chose to report it early on this Form 4.

Insider Trade Summary

Small Acquisition: 6 shares

Small Acquisition 1 txn

Insider CARTER ROBERT B

Role Director

Type	Security	Shares	Price	Value
Small Acquisition	Common Stock	6	$183.51	$1K

Holdings After Transaction: Common Stock — 2,704 shares (Direct)

Footnotes (1)

1. F1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

FAQ

What insider transaction did Quest Diagnostics (DGX) report for Robert B. Carter?

Quest Diagnostics director Robert B. Carter reported acquiring 6 shares of common stock through a dividend reinvestment plan at $183.51 per share. This was a small, routine reinvestment transaction that he chose to report early on Form 4 instead of waiting for Form 5.

How many Quest Diagnostics (DGX) shares does Robert B. Carter now hold?

After the reported dividend reinvestment, Robert B. Carter directly holds 2,704 shares of Quest Diagnostics common stock. This total reflects the addition of 6 shares acquired on January 28, 2026, under his broker’s dividend reinvestment plan.

Was the Quest Diagnostics (DGX) insider transaction a buy or sell?

The transaction was an acquisition of shares, not a sale. Robert B. Carter obtained 6 shares of Quest Diagnostics common stock through a dividend reinvestment plan, which automatically reinvests cash dividends into additional shares of the company.

What price was paid per share in the Quest Diagnostics (DGX) dividend reinvestment?

The 6 shares of Quest Diagnostics common stock were acquired at $183.51 per share through a dividend reinvestment plan. This plan channels cash dividends into purchasing additional shares on behalf of the reporting person automatically.

Why was this Quest Diagnostics (DGX) dividend reinvestment reported on Form 4?

The dividend reinvestment transaction was eligible for deferred reporting on Form 5 under Rule 16a-6, but Robert B. Carter chose to report it early on Form 4. This provides more timely public disclosure of the small share acquisition.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 05:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CARTER ROBERT B

(Last) (First) (Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/28/2026		L	V	6(1)	A	$183.51	2,704	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

Remarks:

	Sean D. Mersten, Attorney-in-Fact for Robert B. Carter	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.